Table 3 Comparison of survival models
From: First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
AIC | BIC | |||
|---|---|---|---|---|
Nivolumab plus ipilimumab | Pemetrexed plus platinum | Nivolumab plus ipilimumab | Pemetrexed plus platinum | |
OS-A | ||||
WeibullPH | 1985.716 | 1968.351 | 1993.143 | 1975.772 |
Log-logistic | 1986.896 | 1954.552 | 1994.323 | 1961.972 |
Log-normal | 1996.288 | 1958.015 | 2003.715 | 1965.436 |
Gompertz | 1989.239 | 1980.054 | 1996.666 | 1987.474 |
Exponential | 1988.198 | 1980.072 | 1991.912 | 1983.782 |
Gamma | 1984.816 | 1963.240 | 1992.244 | 1970.661 |
OS-E | ||||
WeibullPH | 1477.448 | 1473.175 | 1484.315 | 1480.016 |
Log-logistic | 1474.177 | 1470.475 | 1481.044 | 1477.316 |
Log-normal | 1478.411 | 1486.525 | 1485.278 | 1493.366 |
Gompertz | 1480.764 | 1480.351 | 1487.631 | 1487.192 |
Exponential | 1479.087 | 1481.437 | 1482.520 | 1484.858 |
Gamma | 1476.274 | 1471.601 | 1483.141 | 1478.442 |
OS-N | ||||
WeibullPH | 496.9260 | 475.9146 | 501.5341 | 480.5761 |
Log-logistic | 499.4671 | 468.2698 | 504.0752 | 472.9313 |
Log-normal | 502.2192 | 468.3080 | 506.8273 | 472.9695 |
Gompertz | 497.4668 | 482.3946 | 502.0749 | 487.0561 |
Exponential | 496.1016 | 481.7369 | 498.4057 | 484.0676 |
Gamma | 496.8764 | 472.4620 | 501.4845 | 477.1235 |
PFS-A | ||||
WeibullPH | 1583.631 | 1448.885 | 1591.059 | 1456.306 |
Log-logistic | 1536.415 | 1419.132 | 1543.842 | 1426.553 |
Log-normal | 1529.415 | 1429.720 | 1536.842 | 1437.141 |
Gompertz | 1549.582 | 1479.176 | 1557.010 | 1486.597 |
Exponential | 1590.696 | 1488.348 | 1594.409 | 1492.058 |
Gamma | 1590.134 | 1435.329 | 1597.561 | 1442.750 |